Page 5,629«..1020..5,6285,6295,6305,631..5,6405,650..»

Temple Grandin Appearing on Autism Live – Video

Posted: Published on March 2nd, 2013

Temple Grandin Appearing on Autism Live Temple Grandin, considered the most popular and accomplished adult living with autism, will make an appearance on Autism Live Monday, March 4, 2013, at 10:30 am (PST). Grandin will join Autism Live host Shannon Penrod and discuss the latest developments in autism treatment, and share her personal journey overcoming the limitations that were imposed on her as an individual with autism. Grandin will also take viewers' questions live, on-air. Grandin is a doctor of animal science and professor at Colorado State University, bestselling author, autism activist, and consultant to the livestock industry on animal behavior. She has published her insights on autism and animal rights in books, including Animals in Translation, Animals Make Us Human and a memoir entitled Thinking in Pictures. By: AutismLive … Continue reading →

Comments Off on Temple Grandin Appearing on Autism Live – Video

Celebrated Author Temple Grandin to Appear on Autism-Live.com, March 4, 2013

Posted: Published on March 2nd, 2013

Temple Grandin, considered the most accomplished and well-known adult with autism in the world, will discuss her life's journey and answer questions from viewers on the widely popular web show Autism-Live.com, Monday, March 4, 2013. (PRWEB) March 01, 2013 We are honored to have her return to Autism-Live.com as our special guest. Our viewers love her and were giving them more of what they want, says Penrod. Grandin is a doctor of animal science and professor at Colorado State University, bestselling author, autism activist, and consultant to the livestock industry on animal behavior. She has published her insights on autism and animal rights in books, including Animals in Translation, Animals Make Us Human and a memoir entitled Thinking in Pictures. To view previous Autism-Live.com shows featuring Grandin, visit: http://www.youtube.com/playlist?list=PLzpc1lUvttW_tBQV3u_wthGs6MCNgFvov. About Temple Grandin: Dr. Grandin didn't talk until she was three and a half years old, communicating her frustration instead by screaming, peeping, and humming. In 1950, she was diagnosed with autism and her parents were told she should be institutionalized. She tells her story of "groping her way from the far side of darkness" in her book Emergence: Labeled Autistic, a book which stunned the world because, until its publication, … Continue reading →

Comments Off on Celebrated Author Temple Grandin to Appear on Autism-Live.com, March 4, 2013

Ground-breaking Genetic Research Gives Hope for Potential Treatment of Autism's Core Symptoms

Posted: Published on March 2nd, 2013

WASHINGTON, March 1, 2013 /PRNewswire/ --As scientists uncover the precise links between autism and the fragile x gene, potential treatments to reverse many of the core symptoms of both autism and fragile X syndrome (FXS) are moving closer to reality. Nationwide clinical drug trials are already underway and are showing significant success in reversing symptoms of severe social impairment and behavioral issues in participants with autism and FXS, giving hope to families and individuals with these conditions that additional treatments may be on the horizon. "For the first time, we have hope that medicines are within sight that will allow many individuals with fragile X syndrome and autism, who have severe social impairments, to be able to function and interact with others in society," said Robert Miller, Executive Director of the National Fragile X Foundation. While autism is the more commonly known of the two conditions, fragile X syndrome is the most common known genetic cause of autism and autism spectrum disorders. It is also the most common cause of inherited intellectual disability and can cause learning and behavioral disorders that can range from mild to severe. New scientific research has further established the interconnectivity between these two conditions. The … Continue reading →

Comments Off on Ground-breaking Genetic Research Gives Hope for Potential Treatment of Autism's Core Symptoms

Bill requiring insurance coverage for autism pared back

Posted: Published on March 2nd, 2013

A bill to mandate insurance coverage for autism treatment received a drastic makeover Thursday in the Utah Senate, disappointing hundreds of parents who hoped they could soon afford the necessary therapies for their children. In its original form, SB55 would have required insurance coverage for children diagnosed with autism spectrum disorder. About 18,000 such youth live in Utah, said the bills sponsor, Sen. Brian Shiozawa, R-Cottonwood Heights. Realizing the measure lacked the votes to pass either legislative chamber, Shiozawa pared it back Thursday, nixing the insurance and confining it to expansion of a pilot program enacted last year. He is asking to double participants to 500 and raise the age limit to seven. The current pilot program tops out at age six. "Its not my first choice," Shiozawa said of the substitute bill. "After conferring with House and Senate leadership I dont have the support of the insurance industry, and I frankly dont have the votes for the bill in its original form." The latest version of SB55 seeks $1.5 million in one-time funding to expand the pilot program, which Shiozawa believes would yield more accurate statistical data as a result. The original SB55 had estimated state budget costs at … Continue reading →

Comments Off on Bill requiring insurance coverage for autism pared back

UCB In-licenses Parkinson's Drug – Analyst Blog

Posted: Published on March 2nd, 2013

UCB ( UCBJF ) recently announced that it has licensed exclusive global rights to tozadenant (SYN115) for Parkinson's disease from Biotie Therapies. The Candidate Tozadenant is an orally administered, selective inhibitor of the adenosine 2a receptor, which is being developed for the treatment of Parkinson's disease. UCB's decision to in-license the candidate was based on encouraging results from a double-blind, randomized, placebo-controlled phase IIb study that evaluated tozadenant as an adjunctive therapy in levodopa-treated Parkinson's disease patients. Phase III program will be conducted by Biotie for which patient enrolment will start by the first half of 2015. Terms of the Deal UCB and Biotie had initially announced their collaboration in 2010. However, with the in-licensing of tozadenant, the original agreement has been modified. Biotie will now receive an upfront payment of $20 million from UCB. Under the original agreement, Biotie was supposed to receive an additional $340 million on the achievement of future milestones. Under the revised deal, Biotie will receive additional amounts in the low triple-digit millions in total, over the next six years, on the achievement of defined development, regulatory and commercialization milestones. Both UCB and Biotie will work on the ongoing clinical development of this candidate. Manufacturing … Continue reading →

Posted in Parkinson's Treatment | Comments Off on UCB In-licenses Parkinson's Drug – Analyst Blog

Parkinson's disease: Parkin protects from neuronal cell death

Posted: Published on March 2nd, 2013

Mar. 1, 2013 Researchers from Ludwig-Maximilians-Universitaet (LMU) in Munich identify a novel signal transduction pathway, which activates the parkin gene and prevents stress-induced neuronal cell death. Parkinson's disease is the most common movement disorder and the second most common neurodegenerative disease after Alzheimer's disease. It is characterized by the loss of dopamin-producing neurons in the substantia nigra, a region in the midbrain, which is implicated in motor control. The typical clinical signs include resting tremor, muscle rigidity, slowness of movements, and impaired balance. In about 10% of cases Parkinson's disease is caused by mutations in specific genes, one of them is called parkin. "Parkinson-associated genes are particularly interesting for researchers, since insights into the function and dysfunction of these genes allow conclusions on the pathomechanisms underlying Parkinson's disease," says Dr. Konstanze Winklhofer of the Adolf Butenandt Institute at the LMU Munich, who is also affiliated with the German Center for Neurodegenerative Diseases (DZNE). Winklhofer and her colleagues had previously observed that parkin can protect neurons from cell death under various stress conditions. In the course of this project, it became obvious that a loss of parkin function impairs the activity and integrity of mitochondria, which serve as the cellular power … Continue reading →

Posted in Parkinson's Treatment | Comments Off on Parkinson's disease: Parkin protects from neuronal cell death

UCB In-licenses Parkinson's Drug

Posted: Published on March 2nd, 2013

UCB (UCBJY) recently announced that it has licensed exclusive global rights to tozadenant (SYN115) for Parkinsons disease from Biotie Therapies. The Candidate Tozadenant is an orally administered, selective inhibitor of the adenosine 2a receptor, which is being developed for the treatment of Parkinsons disease. UCBs decision to in-license the candidate was based on encouraging results from a double-blind, randomized, placebo-controlled phase IIb study that evaluated tozadenant as an adjunctive therapy in levodopa-treated Parkinson's disease patients. Phase III program will be conducted by Biotie for which patient enrolment will start by the first half of 2015. Terms of the Deal UCB and Biotie had initially announced their collaboration in 2010. However, with the in-licensing of tozadenant, the original agreement has been modified. Biotie will now receive an upfront payment of $20 million from UCB. Under the original agreement, Biotie was supposed to receive an additional $340 million on the achievement of future milestones. Under the revised deal, Biotie will receive additional amounts in the low triple-digit millions in total, over the next six years, on the achievement of defined development, regulatory and commercialization milestones. Both UCB and Biotie will work on the ongoing clinical development of this candidate. Manufacturing and commercialization … Continue reading →

Posted in Parkinson's Treatment | Comments Off on UCB In-licenses Parkinson's Drug

Can nerve endings in the tongue help us treat traumatic brain injury?

Posted: Published on March 2nd, 2013

PITTSBURGH The human tongue is an extraordinary bit of flesh. It's alternately squishy and tense, at times delicate and others powerful. It helps us taste, talk and tie cherry stems, all the while avoiding two interlocking rows of sharpened enamel that know only how to gnash. Now, it seems the tongue may even serve as a gateway to the human brain, providing us with the opportunity to treat serious afflictions from multiple sclerosis to combat-induced brain injuries. The tongue is a natural candidate for electrical stimulation, thanks in part to a high density of sensory receptors and the concentration of electrolytes found in saliva. This has allowed researchers at the Tactile Communication and Neurorehabilitation Laboratory at the University of Wisconsin-Madison to develop a pattern of electrodes that can be placed on the tongue and attached to a control box. All together, the system is called a Portable Neuromodulation Stimulator (PoNS). Once hooked in, patients undergo 20-30 minutes of stimulation therapy, or CN-NiNM (cranial nerve non-invasive neuromodulation), matched to a regimen of physical, occupational and cognitive exercises specific to the ailment being treated. Each exercise corresponds with different patterns of tongue stimulation, which in turn coax the brain to form new … Continue reading →

Posted in Brain Injury Treatment | Comments Off on Can nerve endings in the tongue help us treat traumatic brain injury?

It costs just 82p a day, so why won't the NHS give us the drug that halts MS?

Posted: Published on March 2nd, 2013

Low Dose Naltrexone (LDN) costs 300 a year privately Drug is not available on the NHS as it has not been trialled to combat MS By Anastasia Parks PUBLISHED: 17:00 EST, 2 March 2013 | UPDATED: 17:01 EST, 2 March 2013 In July 2009, my husband took me to Henley Royal Regatta, the scene of many of his youthful triumphs. We enjoyed a long, hot sunny day sipping Pimms. It was bliss, not least because since being diagnosed with multiple sclerosis the summer before, I had become increasingly anxious about outings to beaches or markets, or even parties and weddings. For years, Id been suffering increasing tingling and numbness in my limbs that became impossible to ignore. A clicking hip while pregnant with my youngest son now seven was followed by weakness in my leg, numbness in both feet, night cramps and weak bladder control. After myriad appointments, tests and MRI scans, I received my diagnosis: primary progressive multiple sclerosis. Patient choice: Anastasia Parks has to buy Low Dose Naltrexone privately This is an uncommon form of the neurological condition which progresses inexorably. But like all variations of MS, in which the immune system turns inward and attacks the nervous … Continue reading →

Posted in MS Treatment | Comments Off on It costs just 82p a day, so why won't the NHS give us the drug that halts MS?

Oxford Neurologist Awarded Dystel Prize for MS Research

Posted: Published on March 2nd, 2013

Newswise SAN DIEGO The American Academy of Neurology and the National Multiple Sclerosis Society are awarding the 2013 John Dystel Prize for MS Research to George C. Ebers, MD, a leading researcher with the University of Oxford and Oxford University Hospitals Trust in Oxford, United Kingdom. Ebers will receive the award at the Academys 65th Annual Meeting in San Diego, March 16-23, 2013. The Annual Meeting is the worlds largest gathering of neurologists with more than 10,000 attendees and more than 2,300 scientific presentations on the latest research advancements in brain disease. The John Dystel Prize recognizes a significant contribution to research in the understanding, treatment or prevention of multiple sclerosis (MS). Ebers research has focused on genetic and environmental influences on MS risks. We have found that MS risk factors previously considered to be genetic can be changed based on environment, strongly implicating gene-environment interaction. Our studies highlight how climate and diet relate to factors leading to MS, which can be views as a largely preventable disease. Vitamin D exposure appears to be the main factor determining geographical risk said Ebers. This award is made possible through a special contribution from the John Dystel Multiple Sclerosis Research Fund at … Continue reading →

Posted in MS Treatment | Comments Off on Oxford Neurologist Awarded Dystel Prize for MS Research

Page 5,629«..1020..5,6285,6295,6305,631..5,6405,650..»